Next-Generation Treatments for High-Risk and Relapsed Patients
Through the Advanced Cancer Therapies Center at Cincinnati Children’s Hospital Medical Center, highly trained oncologists subspecializing in specific childhood cancers treat patients with high risk and relapsed disease using the most advanced therapies available.
The faculty of the Advanced Cancer Therapies Center are developing and refining the next generation of innovative treatments through the robust laboratory and translational research programs within the Cancer and Blood Diseases Institute at Cincinnati Children’s and through their leadership in national pediatric cancer research consortia.
- Cincinnati Children’s faculty are national leaders in the National Cancer Institute (NCI) Pediatric Phase I Consortium, the Children’s Oncology Group (COG), the New Approaches to Neuroblastoma Consortium (NANT), the Collaborative Ependymoma Research Network (CERN), the Neurofibromatosis Clinical Consortium, and other leading pediatric cancer clinical research consortia.
- Close collaborations among faculty in the Division of Oncology, the Division of Bone Marrow Transplantation and Immune Deficiency, and the Division of Experimental Hematology and Cancer Biology – as well as other Divisions and programs across Cincinnati Children’s – allow the rapid development of novel therapies such as oncolytic viruses, therapeutic antibodies, and novel signal transduction inhibitors.
- A pediatric cancer drug discovery program uses an industry-grade compound library to screen for potential new drugs to fight pediatric cancers, which are then refined and tested in our laboratories.
- A new Radiobiologics Therapy Program is developing new treatments for high risk neuroblastoma and leukemia / lymphoma.
- New laboratory initiatives are developing the capability to rapidly analyze patient tumors for specific genetic mutations to help direct patients to the most appropriate novel targeted drugs.
For more information about the Advanced Cancer Therapies Center, contact:
John Perentesis, MD, FAAP
Director of Oncology Division